ADHD Clinical and Translational Studies Program

Our Team

Jeffrey Newcorn, MD

Professor Department of Psychiatry, Medical Director Division of ADHD, Learning Disabilities, and Related Disorders
Director, Center for Excellence in ADHD and Related Disorders
Director, ADHD Clinical and Translational Studies Program Director, Pediatric Psychopharmacology at the Mount Sinai Health System Profile  • Profile  •  Dr. Newcorn’s CV 2018

Call: 212-659-8775

Iliyan Ivanov, MD

Associate Professor Department of Psychiatry; Medical Director CARES Program Mount Sinai Health System. Center for Excellence in ADHD and Related Disorders, ADHD Clinical and Translational Studies Program Icahn School of Medicine at Mount Sinai Profile  • Profile   •  Dr. Ivanov’s CV 2018
Email: Call: 212-523-3153

Kurt Schulz, PhD

Assistant Professor Psychiatry, Icahn School of Medicine at Mount Sinai
Dr. Schulz’s CV 2018

Call: 212-241-6623

Beth Krone, PhD

Assistant Professor Psychiatry Icahn School of Medicine Mount Sinai, Research Manager Clinical and Translational Studies Program Division of ADHD, Learning Disabilities, and Related Disorders, Center for Excellence for ADHD and Related Disorders, NYS Licensed Clinical Psychologist

Dr. Krone’s CV 2019   •  Orcid ID  •  Scopus ID  •  Researcher ID

Email: Call: 212-241-8012 or 646-535-1618

Nicole Doctoroff, BA

Clinical Research Coordinator


Research Partners

ADHD Research

The ADHD Clinical and Translational Studies Program


The ADHD Clinical and Translational Studies Program is uniquely situated at the heart of one of the world’s premier academic medical centers. Our international collaborations with world-class clinicians and scientists has produced (and keeps producing) critical insights into the development, presentation, consequences, and treatment of ADHD and related disorders throughout the lifespan. 

As part of the Division of ADHD, Learning Disabilities, and Related Disorders at the Icahn School of Medicine at Mount Sinai, our scientists are highly regarded educators and clinicians who provide learning experiences for trainees while producing the scientific evidence that informs our senior colleagues’ practice and research in the field. Our program contributes to the high ranking of our Psychiatry Department, as the #6 recipient of NIH funding for research in the United States. 

As an integral part of the Center for Excellence for ADHD and Related Disorders at the Mount Sinai Health System, we take our commitment to patient care very seriously. This means that our patients receive top quality and cutting-edge care.  

Jeffrey Newcorn, M.D.

Professor, Department of Psychiatry
Medical Director, Division of ADHD, Learning Disabilities, and Related Disorders
Director, Center for Excellence in ADHD and Related Disorders
Director, ADHD Clinical and Translational Studies Program
Director, Pediatric Psychopharmacology at the Mount Sinai Health System

Contact Us

Phone: 212-659-8775

Current Projects


We currently hold three NIH funded grants researching ADHD among youth, employing cutting edge neuroimaging, pharmacogenetics, and genomics in human translational research:

We are conducting two R21 pilot studies (NCT03781765) to determine if there are differing neurobiological effects in the brain’s reward system between a group of youth with ADHD and a group of youth with ADHD+ Conduct Disorder (CD) OR ADHD + severe Oppositional Defiant Disorder (ODD), and whether these differences are magnified or reduced when treated with commonly prescribed, FDA approved stimulant or non-stimulant medications. For these studies, previously untreated youths ages 8 to 12 years old are evaluated and treated by our team of expert clinicians. Our neuroscience team will capture baseline and post treatment functional magnetic resonance images while children play videogame-based neuropsychological tasks that capture medication mediated change. These studies will serve as a basis for larger grants exploring the effects of these medications

We are the clincial coordinating center for a nation-wide study (NCT03781752) to determine the impact of carboxylesterase (CES1) gene variants on metabolism of the most commonly prescribed, FDA approved stimulant medication for treatment for ADHD. CES1 genes are responsible for producing the enzymes that breakdown several classes of drugs, including methylphenidates (MPH), in the liver. For this study, our treatment teams will monitor treatment of youth ages 6 to 17 years old in clinical practice. Youth with genotypes of interest will be asked to complete a pharmacokinetic procedure to assess group differences in MPH metabolism. Results of this study will inform personalized treatments and application of precision medicine in clinical decision making, with the goal of reducing the time between diagnosis and finding effective treatment, and reducing side effect risks.

Our most recent industry sponsored clinical studies are focused on a number of areas:

We are treating adults ages 18 to 55 years with ADHD using a new, non-stimulant drug called Centanafadine (NCT03605849) to determine whether it is effective and safe for treating ADHD

We currently are conducting two studies of Molindone (NCT02691182). Our doctors are treating youth ages 6 to 12 years old, who are receiving an FDA approved medication for ADHD according to best clinical practice guidelines, but who continue to experience impairing outbursts of impulsive aggression, in concert with their own prescribing physicians to optimize care. This study seeks to determine the efficacy of Molindone for aggression among youth with ADHD.

Recent Publications


Michael J. Silverstein, BA; Terry L. Leon, MS, RN; Beth Krone, PhD; Stephen V. Faraone, PhD; Jeffrey H. Newcorn, MD; Lenard A. Adler, MD (2019). The Characteristics and Unique Impairments of Comorbid Adult ADHD and Sluggish Cognitive Tempo: An Interim Analysis. Psychiatric Annals. 2019;49(10):457-465.

Connor DF, Newcorn JH, Saylor KE, Amann BH, Scahill L, Robb AS, Jensen PS, Vitiello B, Findling RL, Buitelaar JK. Maladaptive Aggression: With a Focus on Impulsive Aggression in Children and Adolescents. J Child Adolesc Psychopharmacol. 2019 Oct;29(8):576-591. doi: 10.1089/cap.2019.0039. Epub 2019 Aug 27. Free PMC Article

Schulz, KP, Bédard, A-CV, Fan, J, Hildebrandt, TB, Stein, MA, Ivanov, I, Halperin, JM, Newcorn, JH. (2017). Striatal Activation Predicts Differential Therapeutic Responses to Methylphenidate and Atomoxetine. J Am Acad Child Adolesc Psychiatry. Jul;56(7):602-609.e2. doi: 10.1016/j.jaac.2017.04.005. Epub 2017 May 10. PMID: 28647012

Faraone SV, Rostain AL, Montano CB, Mason O, Antshel KM, Newcorn JH. Systematic Review: Nonmedical Use of Prescription Stimulants: Risk Factors, Outcomes, and Risk Reduction Strategies. J Am Acad Child Adolesc Psychiatry. 2019 Jul 18. pii: S0890-8567(19)30470-8. doi: 10.1016/j.jaac.2019.06.012. [Epub ahead of print] Review. Free Article

Newcorn, JH., Krone, B., Hildebrandt, T, & Stein, M. (2017). Methylphenidate vs. Atomoxetine in Youth with ADHD: Comparative Effectiveness and Preference following Treatment with both Medications. Biological Psychiatry. DOI: 10.1016/j.biopsych.2017.02.581

Ivanov I, Schulz K, Li X, Newcorn J. Reward Processing in Drug-Naive Youth with Various Levels of Risk for Substance Use Disorders: A Pilot Study. J Child Adolesc Psychopharmacol. 2019 Aug;29(7):516-525. doi: 10.1089/cap.2018.0175. Epub 2019 Jun 10. PMID:31180232

Faraone, S, Rostain, AL, Blader, J, Busch, B, Childress, A, Connor, D, Newcorn, JH. (2018). Practitioner Review: Emotional Dysregulation in ADHD – Implications for Clinical Recognition and Intervention. J Child Psychol Psychiatry Apr 6. doi: 10.1111/jcpp.12899. [Epub ahead of print] Review. PMID: 29624671

Schulz, KP, Krone, B, Adler, LA, Bédard, A-CV, Duhoux, S, Pedraza, J, Mahagabin, S, Newcorn, JH. Lisdexamfetamine Targets Amygdala Mechanisms that Bias Cognitive Control in Attention Deficit Hyperactivity Disorder. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging 2018 Mar 19. pii: S2451-9022(18)30067-3. doi: 10.1016/j.bpsc.2018.03.004. [Epub ahead of print] PMID: 29661516

Selected Texts


Krone, B, Ivanov, I & Newcorn, J. (2019). Aggression in Disruptive Behavior Disorders. In Coccaro & McCloskey (Eds) Aggression: Clinical Features and Treatment Across the Diagnostic Spectrum. American Psychiatric Association

Krone, B & Newcorn, J. ADHD (2019). In: Alosco & Stern (Eds.) The Oxford Handbook of Adult Cognitive Disorders. Oxford University Press 

Krone, B & Newcorn, JH (2015). Comorbidity of ADHD and Anxiety Disorders: Descriptive and Clinical Features, Diagnosis and Treatment Across the Lifespan. In: Adler, Wilens, Spencer (Eds.) Attention-Deficit Hyperactivity Disorder in Adults and Children. Cambridge University Press

Newcorn, JH, Leikauf, J, Johnson, B, Krone, B, Halperin, JM (2015). Attention-deficit/Hyperactivity Disorder. In: A. Tasman, J. Kay, J.A. Lieberman (Eds.) Psychiatry, 4th edition. W.B. Saunders: Philadelphia

Dr. Lenard Adler, M.D. is a long-time collaborator, colleague, and friend to our lab. Our most recent joint works included a study of the cognitive and neurocognitive correlates of Sluggish Cognitive Tempo (SCT) among adults with ADHD.

Dr. James Blair, Ph.D. is a world renowned expert on the neurobiology of aggression. He has most recently collaborated with us on neuroimaging studies of the emotional biasing of cognition and amygdala activation among adults with ADHD, and his team is currently consulting on our NIH funded pilot studies of the neurobiological predictors of substance abuse among youth with aggression.

Dr. John Markowitz, Pharm.D. is another long-time collaborator, colleague, and friend who is the current Principal Investigator of our translational R01 study funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development

Dr. Tanya Froehlich, M.D. is a pediatrician who has been conducting molecular research in ADHD. She is a clinical collaborator on our current R01 examining genetic markers of methylphenidate metabolism.

Dr. Haojie Zhu, Ph.D. studies Pharmacogenomics, Pharmacokinetics, and Neuropsychopharmacology, focusing on identifying both genetic variations and environmental factors that impact pharmacokinetics and pharmacodynamics of various therapeutic agents. he is a collaborator on our multi-state R01 examining methylphenidate metabolism.

Dr. Mark Stein, Ph.D. is has been a collaborator, colleague, and friend who has worked closely with our team on large-scale, NIH funded clinical trials of ADHD in youth. He is currently a collaborator on our multi-site pharmacogenetics study of CES metabolism and ADHD.

Dr. Jin Fan, Ph.D. ia a world renowned cognitive neuroscientist who has guided our neuroimaging work for decades. Dr. Fan is continues to mentor Dr. Schulz’s work on response inhibition, and executive control in ADHD

Clinical Practice


The Clinical and Translational studies program is part of the Center for Excellence for ADHD and Related Disorders at the Mount Sinai Health System and the Department of Psychiatry at the Icahn School of Medicine at Mount Sinai. Our doctors work in the clinical programs and practices at Mount Sinai.

For more information about Dr. Newcorn’s Clinical Faculty Practice, please call his clinical practice coordinator at 212-659-8705.

To learn more about our clinical behavioral program for children, adolescents, adults, and parents with ADHD, visit

Clinical Practice
19 East 98th Street
Phone: 212-659-8705


Administrative Offices
1 Gustave L Levy Place, Box 1230
Phone: 212-241-8012

Data Lab
19 East 98th Street
Phone: 212-241-6623

Research Program
19 East 98th Street
Phone: 212-241-5326